Literature DB >> 8363266

Rapamycin: in vitro profile of a new immunosuppressive macrolide.

S N Sehgal1, C C Bansbach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8363266     DOI： 10.1111/j.1749-6632.1993.tb35852.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  12 in total

Review 1.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

2.  Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Ruth-Anne Langan; Alberto Sada Japp; Helen L Partridge; Sheila K Pierson; Amrit Singh; Daniel J Arenas; Jason R Ruth; Christopher S Nabel; Katie Stone; Mariko Okumura; Anthony Schwarer; Fábio Freire Jose; Nelson Hamerschlak; Gerald B Wertheim; Michael B Jordan; Adam D Cohen; Vera Krymskaya; Arthur Rubenstein; Michael R Betts; Taku Kambayashi; Frits van Rhee; Thomas S Uldrick
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

Review 3.  Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.

Authors:  Andras Perl
Journal:  Nat Rev Rheumatol       Date:  2015-12-24       Impact factor: 20.543

Review 4.  Vascular smooth muscle cell proliferation in restenosis.

Authors:  Steven O Marx; Hana Totary-Jain; Andrew R Marks
Journal:  Circ Cardiovasc Interv       Date:  2011-02-01       Impact factor: 6.546

5.  Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.

Authors:  Zhi-Wei Lai; Ryan Kelly; Thomas Winans; Ivan Marchena; Ashwini Shadakshari; Julie Yu; Maha Dawood; Ricardo Garcia; Hajra Tily; Lisa Francis; Stephen V Faraone; Paul E Phillips; Andras Perl
Journal:  Lancet       Date:  2018-03-15       Impact factor: 79.321

6.  Multiple cis-trans conformers of the prolactin receptor proline-rich motif (PRM) peptide detected by reverse-phase HPLC, CD and NMR spectroscopy.

Authors:  K D O'Neal; M V Chari; C H Mcdonald; R G Cook; L Y Yu-Lee; J D Morrisett; W T Shearer
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

7.  Sirolimus (rapamycin) inhibits mitogen-induced stimulation of protein synthesis in primary lymphocytes.

Authors:  C C Bansbach; D Wancio; S N Sehgal
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

Review 8.  Nano and Microparticle Emerging Strategies for Treatment of Autoimmune Diseases: Multiple Sclerosis and Type 1 Diabetes.

Authors:  Alexander J Kwiatkowski; Joshua M Stewart; Jonathan J Cho; Dorina Avram; Benjamin G Keselowsky
Journal:  Adv Healthc Mater       Date:  2020-04-27       Impact factor: 9.933

9.  Islet cell transplantation.

Authors:  Terry Samuel; Paul Cockwell
Journal:  J R Soc Med       Date:  2002-01       Impact factor: 18.000

Review 10.  mTOR as a central hub of nutrient signalling and cell growth.

Authors:  Joungmok Kim; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2019-01-02       Impact factor: 28.824
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.